[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100505102":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":29,"centralContacts":35,"locations":41,"responsibleParty":132,"collaborators":29,"id":134,"slug":135,"hasResults":136,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":29,"eligibilityCriteria":140,"healthyVolunteers":136,"sex":141,"minAge":142,"maxAge":29,"enrollmentInfo":143,"targetDuration":29,"studyType":146,"phases":147,"briefSummary":149,"conditions":150,"keywords":158,"overallStatus":44,"whyStopped":29,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":169},{"fullName":5,"class":6},"Sairopa B.V.","INDUSTRY",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Monotherapy dose escalation, IV, Q3W, multiple dose levels","EXPERIMENTAL","ADU-1805 monotherapy dose escalation",[13],"Drug: ADU-1805",{"label":15,"type":10,"description":16,"interventionNames":17},"Combination dose escalation, IV, Q3W, multiple dose levels, pembrolizumab at fixed dose","ADU-1805 plus pembrolizumab dose escalation",[13,18],"Drug: Pembrolizumab",{"label":20,"type":10,"description":21,"interventionNames":22},"Combination dose expansion, IV, Q3W, multiple dose levels, pembrolizumab at fixed dose","ADU-1805 plus pembrolizumab dose expansion",[13,18],[24,30],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","ADU-1805","anti-SIRPα monoclonal antibody",[15,20,9],null,{"type":25,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"Pembrolizumab","Keytruda",[15,20],[32],[36],{"name":37,"role":38,"phone":39,"phoneExt":29,"email":40},"Sairopa Clinical Team","CONTACT","0031 85 90 26 939","clinical@sairopa.com",[42,59,72,85,98,111,124],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Henry Ford Cancer Institute","RECRUITING","Detroit","Michigan","48202","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-83.04575,42.33143,{"lat":54,"lon":53},[57],{"name":58,"role":38,"phone":29,"phoneExt":29,"email":29},"Weise, Dr.",{"facility":60,"status":44,"city":61,"state":62,"zip":63,"country":48,"countryCode":49,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"Washington University Medical Campus","St Louis","Missouri","63110",{"type":51,"coordinates":65},[66,67],-90.19789,38.62727,{"lat":67,"lon":66},[70],{"name":71,"role":38,"phone":29,"phoneExt":29,"email":29},"Khushman, Dr.",{"facility":73,"status":44,"city":74,"state":75,"zip":76,"country":48,"countryCode":49,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Gabrail Cancer & Research Center","Canton","Ohio","44718",{"type":51,"coordinates":78},[79,80],-81.37845,40.79895,{"lat":80,"lon":79},[83],{"name":84,"role":38,"phone":29,"phoneExt":29,"email":29},"Gabrail, Dr.",{"facility":86,"status":44,"city":87,"state":88,"zip":89,"country":48,"countryCode":49,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Virginia Cancer Specialists","Fairfax","Virginia","22205",{"type":51,"coordinates":91},[92,93],-77.30637,38.84622,{"lat":93,"lon":92},[96],{"name":97,"role":38,"phone":29,"phoneExt":29,"email":29},"Spira, Dr.",{"facility":99,"status":44,"city":100,"state":29,"zip":29,"country":101,"countryCode":102,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"Grand Hopital de Charleroi (GHdC) - Hopital Notre Dame","Charleroi","Belgium","BE",{"type":51,"coordinates":104},[105,106],4.44448,50.41136,{"lat":106,"lon":105},[109],{"name":110,"role":38,"phone":29,"phoneExt":29,"email":29},"Schroeder, Dr.",{"facility":112,"status":44,"city":113,"state":29,"zip":29,"country":114,"countryCode":115,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"Hosp 12 de Octubre","Madrid","Spain","ES",{"type":51,"coordinates":117},[118,119],-3.70256,40.4165,{"lat":119,"lon":118},[122],{"name":123,"role":38,"phone":29,"phoneExt":29,"email":29},"de Velasco, Dr.",{"facility":125,"status":44,"city":113,"state":29,"zip":29,"country":114,"countryCode":115,"cosmosGeoPoint":126,"geoPoint":128,"contacts":129},"Hospital General Universitario Gergorio Maranon",{"type":51,"coordinates":127},[118,119],{"lat":119,"lon":118},[130],{"name":131,"role":38,"phone":29,"phoneExt":29,"email":29},"Calvo, Dr.",{"type":133,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100505102","phase-1-phase-1-study-evaluating-the-safety-and-pk-of-adu-1805-in-advanced-solid-tumors-100505102",false,"NCT05856981","Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors","An Open-Label, Multicenter, Multi-arm Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1805 in Adults With Advanced Solid Tumors","Inclusion Criteria:\n\n* Male or female aged ≥18 years\n* Signed and dated informed consent form\n* Measurable disease according to RECIST (Safety Expansion only)\n* ECOG Performance status of 0 or 1\n* Adequate organ and marrow function\n* Escalation Phase: Histologically and\u002For cytologically confirmed diagnosis of metastatic or unresectable solid tumors that are refractory to standard therapy or for which no standard therapy exists\n* Expansion Phase: histologically and\u002For cytologically confirmed diagnosis of advanced PD-(L)1-naïve MSS colorectal cancer (CRC), PD-1 relapsed\u002Frefractory patients with either advanced MSS endometrial cancer (EC), renal cell carcinoma (RCC) or non-small cell lung cancer (NSCLC) patients, and that have measurable disease according to RECIST\n\nExclusion Criteria:\n\n* Escalation Phase: Patients that suffer from melanoma, brain tumors, glioblastoma, sarcoma and pancreatic ductal adenocarcinoma (PDAC)\n* Expansion Phase:\n\n  * \\> 3 lines of prior systemic treatments\n  * MSS colorectal cancer (CRC): liver metastasis present\n* Pregnancy or breast-feeding\n* Prior treatment with or receipt of:\n\n  * biological agents, including monoclonal antibodies and immunotherapies, within 28 days prior to the first dose of ADU-1805\n  * chemotherapy, targeted small molecule therapy, hormonal therapy or radiation therapy within 21 days prior to the first dose of ADU-1805 and within 42 days for nitrosoureas and mitomycin C.\n  * anti-SIRPα or anti-CD47-directed therapy\n  * systemic chronic steroid therapy or immunosuppressive therapy within 14 days prior to the first dose of ADU-1805\n  * other investigational new drug or investigational device within 28 days prior to the first dose of ADU-1805\n  * vaccine containing live virus within 28 prior to the first dose of ADU-1805\n* Active untreated brain metastases\n* Active infection requiring systemic therapy\n* Impaired cardiac function or clinically significant cardiac disease\n* Current Grade \\>2 toxicity related to prior anti-cancer therapy\n* History of drug-induced severe immune-related adverse reaction\n* Prior severe hypersensitivity to other monoclonal antibodies or ADU-1805 excipients\n* Major surgery within defined period\n* Diagnosis or positive test of HIV, hepatitis B, hepatitis C, or active tuberculosis\n* Allogenic tissue\u002Fsolid organ transplant\n* Any intercurrent illness that is life-threatening or of such clinical significance that it would interfere with the patient's safety or ability to participate in the study","ALL","18 Years",{"count":144,"type":145},130,"ESTIMATED","INTERVENTIONAL",[148],"PHASE1","This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPα monoclonal antibody, as monotherapy and in combination with pembrolizumab (anti-PD-1 antibody).",[151,152,153,154,155,156,157],"Solid Tumor, Adult","Metastatic Solid Tumor","Refractory Cancer","CRC, Colorectal Cancer","RCC, Clear Cell Adenocarcinoma","NSCLC (Advanced Non-small Cell Lung Cancer)","Endometrial Cancer",[159],"Immunotherapy","2025-12-09",{"date":162,"type":163},"2025-12-17","ACTUAL",{"date":165,"type":163},"2023-04-03",{"date":167,"type":145},"2027-07",{"name":5,"class":6},7]